Stereotaxis Inc. STXS
- Market cap
- $133.3M
- P/E
- 0.0×
Follow STXS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.47 | 0.48 | 0.51 | 1.07 | 1.70 | 4.31 | 1.55 | 1.33 | 1.66 | 1.54 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 1.95 | 1.10 | 1.65 | 5.82 | 5.58 | 10.30 | 7.22 | 2.75 | 3.29 | 3.59 |
High Price
|
|||
| 120 | 117 | 119 | 118 | 120 | 130 | 130 | 122 | 139 | 131 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 32 | 31 | 29 | 29 | 27 | 35 | 28 | 27 | 27 | 32 |
Revenue
|
|||
| 76.59% | 65.47% | 80.52% | 78.77% | 71.22% | 66.34% | 65.62% | 55.51% | 54.22% | 52.73% |
Gross Margin
|
|||
| (5) | (6) | 0 | (5) | (7) | (11) | (18) | (21) | (24) | (22) |
EBT
|
|||
| (16.44%) | (18.90%) | 0.40% | (15.89%) | (24.96%) | (30.60%) | (64.99%) | (77.37%) | (89.33%) | (66.85%) |
EBT Margin
|
|||
| (5) | (6) | 0 | (5) | (7) | (11) | (18) | (21) | (24) | (22) |
Net Income
|
|||
| 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Depreciation
|
|||
| 1.47 | 1.38 | 0.56 | 0.46 | 0.37 | 0.46 | 0.37 | 0.33 | 0.32 | 0.36 |
Revenue/Sh
|
|||
| (0.54) | (0.32) | (0.03) | (0.10) | (0.11) | (0.16) | (0.26) | (0.27) | (0.30) | (0.25) |
Earnings/Sh
|
|||
| (0.30) | (0.21) | (0.05) | (0.07) | (0.05) | (0.04) | (0.11) | (0.11) | (0.10) | (0.15) |
Cash Flow/Sh
|
|||
| (0.02) | 0.00 | (0.01) | 0.00 | 0.00 | (0.02) | (0.03) | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.32) | (0.21) | (0.05) | (0.07) | (0.05) | (0.06) | (0.14) | (0.12) | (0.10) | (0.15) |
Free CF/Sh
|
|||
| (0.71) | (0.91) | 0.14 | 0.45 | 0.55 | 0.52 | 0.42 | 0.27 | 0.13 | 0.21 |
Book Value/Sh
|
|||
| 22 | 23 | 52 | 63 | 73 | 76 | 76 | 81 | 85 | 91 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.47 | 0.61 | 1.92 | 11.54 | 13.90 | 13.38 | 5.67 | 5.64 | 7.22 | 6.46 |
PS Ratio
|
|||
| 0.00 | 0.00 | 42.90 | 14.65 | 10.70 | 13.85 | 6.06 | 9.23 | 31.94 | 15.52 |
PB Ratio
|
|||
| 0.87 | 1.17 | 2.27 | 10.65 | 12.41 | 12.43 | 4.85 | 5.09 | 6.96 | 6.22 |
EV/Sales
|
|||
| (3.94) | (7.66) | (23.67) | (66.23) | (91.91) | (100.25) | (12.66) | (14.32) | (21.96) | (14.61) |
EV/FCF
|
|||
| (7) | (5) | (3) | (5) | (4) | (3) | (8) | (9) | (8) | (14) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | (1) | (2) | 0 | 0 | 0 |
Capex
|
|||
| (7) | (5) | (3) | (5) | (4) | (4) | (11) | (10) | (9) | (14) |
FCF
|
|||
| (16) | (20) | 8 | 27 | 39 | 38 | 29 | 20 | 5 | 11 |
Working Cap'
|
|||
| — | — | — | 2 | 1 | 6 | 5 | — | — | — |
Total Debt
|
|||
| (9) | (4) | (11) | (28) | (43) | (33) | (23) | (20) | (12) | (13) |
Net Debt
|
|||
| (16) | (21) | 7 | 29 | 40 | 39 | 32 | 22 | 11 | 19 |
Sh' Equity
|
|||
| (59.23%) | (46.28%) | (9.03%) | (19.39%) | (16.19%) | (20.72%) | (34.33%) | (46.28%) | (57.21%) | (46.30%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | (698.34%) | 0.00% | (132.58%) | (138.68%) | (865.53%) | 0.00% | (260.75%) |
ROIC
|
|||
| 60.34% | 30.46% | 10.43% | (50.02%) | (27.94%) | (35.24%) | (65.26%) | (103.35%) | (226.13%) | (234.28%) |
ROE
|
|||
Stereotaxis Inc. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NYXH Nyxoah SA | $129.3M | 0.0× | Compare |
| KRMD KORU Medical Systems, Inc. | $151.0M | 0.0× | Compare |
| ZJYL Jin Medical International Ltd. | $159.2M | — | Compare |
| MBOT Microbot Medical Inc. | $88.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PDEX Pro-Dex, Inc. | $233.9M | 17.0× | Compare |
| UTMD Utah Medical Products, Inc. | $238.0M | 22.7× | Compare |
| DXR Daxor Corporation | $66.5M | 5.1× | Compare |
| OSUR OraSure Technologies, Inc. | $271.1M | 0.0× | Compare |
Stereotaxis Inc. (STXS) key facts
- Stereotaxis Inc. (STXS) is a Medical Instruments & Supplies company in the Healthcare sector, listed on NYSE American.
- Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024.
- As of September 25, 2026, STXS traded at $1.30, a market capitalization of $133.3 million.
- Return on equity was −234.3% and debt-to-equity 0.00.
Stereotaxis Inc. (STXS) Latest News
16 Sep
Stereotaxis Inc. will showcase emerging digital, AI and automation capabilities at the Heart Rhythm Society’s HRX 2026 event. Showcasing AI and automation technologies at a major industry conference may boost product innovation visibility and competitive positioning in cardiac robotics.
18 Aug
Stereotaxis Inc. (STXS) Q2 2026 earnings call transcript released covering financial results and operations. Q2 2026 earnings details can moderately shift near-term investor sentiment and stock performance.
12 Aug
Stereotaxis Inc. (STXS) Q2 2026 earnings call covered financial results, revenue performance, operational updates, and forward guidance. Q2 2026 earnings call supplies financial metrics and strategy updates with moderate influence on near-term performance.
11 Aug
Stereotaxis Inc. Q2 earnings call covered financial results, operational updates and strategic outlook. Quarterly earnings updates provide performance details that moderately influence near-term sentiment without major strategic shifts.
Stereotaxis Inc. reported second quarter 2026 financial results and business updates. Quarterly financial results and updates supply performance metrics that can shift near-term investor views and trading.
20 Jul
University of Szeged launches Hungary's first robotic cardiology program using Stereotaxis technology. First national adoption of Stereotaxis systems adds new Eastern European reference site and modest revenue potential.
9 Jul
Stereotaxis Inc. completes takeover of Robocath. Takeover expands Stereotaxis robotic systems portfolio and competitive reach in electrophysiology.
Stereotaxis Inc. completed acquisition of Robocath. Acquisition of Robocath expands Stereotaxis robotic navigation portfolio and market presence.
29 Jun
Citizens identifies Stereotaxis' razor/razor blade ecosystem as a compelling driver of sustainable growth. Analyst view on ecosystem strength may moderately lift investor sentiment and near-term stock perception.
15 May
Stereotaxis reported Q1 financial results on its earnings call, highlighting revenue, operational progress with robotic navigation systems, and updated guidance for cardiac ablation technology adoption. Q1 earnings updates detail financials and pipeline progress that moderately influence near-term sentiment without major strategic shifts.
13 May
Stereotaxis Inc. (STXS) Q1 2026 earnings call highlights regulatory wins amid revenue navigation challenges. Regulatory wins in Q1 earnings call indicate significant advancements for STXS's medtech pipeline and competitive positioning.
Stereotaxis Inc. released Q1 2026 earnings call details covering financial results, operations, and outlook for STXS. Q1 earnings call provides financial updates and guidance that can moderately affect STXS stock and near-term sentiment.
12 May
Stereotaxis Inc. (STXS) reported first quarter 2026 financial results and provided business updates. Quarterly earnings reports with business updates directly affect financial performance, investor sentiment, and stock trajectory.
Stereotaxis Inc. (STXS) reported a first-quarter loss and revenue below analyst estimates. Q1 loss and revenue miss highlight financial underperformance, likely affecting near-term stock price and investor sentiment.
1 May
Stereotaxis Inc. (STXS) emerges as one of the top robotics stocks to buy under $30, driven by innovative magnetic navigation technology for cardiac procedures, growing adoption, strong clinical data, undervalued price, and expanding market opportunities. Endorsement as a leading affordable robotics stock highlights growth potential and undervaluation, likely influencing investor sentiment and moderate financial performance without transformative events.
23 Apr
Stereotaxis Inc. (STXS) stock rose sharply after the first U.S. procedures using its MAGiC robotic system post-FDA approval, marking initial commercial adoption. First U.S. MAGiC procedures post-approval demonstrate successful commercialization entry, driving stock gains and enhancing revenue prospects.
22 Apr
Stereotaxis Inc. announces the first MAGiC procedures performed in the United States. First U.S. MAGiC procedures represent a major milestone in commercial rollout of Stereotaxis' robotic system, boosting adoption and revenue potential.
17 Apr
Stereotaxis Inc. (STXS) announces acquisition of Robocath to establish leadership in the endovascular robotics market. Acquisition of Robocath positions STXS as endovascular robotics leader, fundamentally redefining its competitive position and long-term prospects.
16 Apr
Stereotaxis Inc. (STXS) announces agreement to acquire Robocath for up to $45 million, enhancing its robotic cardiology platform with complementary catheterization technology. Acquisition of Robocath for up to $45m bolsters Stereotaxis' product pipeline and competitive edge in robotic interventions.
15 Apr
Stereotaxis Inc. (STXS) announces a definitive agreement to acquire Robocath, a developer of robotic solutions for vascular interventions, aiming to expand its cardiology robotics platform. Definitive acquisition agreement enables major strategic expansion into vascular robotics, significantly boosting Stereotaxis' product portfolio and market position.
Stereotaxis Inc. (STXS) to acquire Robocath for up to $45 million in a strategic deal to expand its robotic cardiology technology portfolio. Acquisition of Robocath for up to $45M is a major strategic move enhancing Stereotaxis's position in robotic catheterization.
7 Apr
Stereotaxis Inc. (STXS) shares gained after FDA clearance for its Synchrony System, enabling expansion in digital surgery. FDA clearance for Synchrony System triggers stock gains and advances STXS in digital surgery, significantly boosting competitive position and investor sentiment.
6 Apr
Stereotaxis Inc. (STXS) announces FDA 510(k) clearance and U.S. launch of the Synchrony System, an advanced robotic magnetic navigation platform for cardiac ablation procedures offering improved precision, safety, and workflow efficiency. FDA clearance and launch of Synchrony System enable commercialization of cutting-edge robotic technology, significantly boosting revenue potential, market adoption, and competitive positioning in electrophysiology.
2 Apr
Intuitive Surgical faces intensifying competition in China from Stereotaxis, raising doubts about defending its robotic surgery market dominance. Stereotaxis emerges as a direct challenger to Intuitive Surgical's China position, signaling major growth opportunities and market share gains.
9 Mar
Stereotaxis Inc. (STXS) reported revenue surge and strategic advances in Q4 2025 earnings call highlights. Revenue surge and strategic advances indicate major positive shifts in financial performance and competitive positioning for STXS.
Stereotaxis Inc. (STXS) released Q4 earnings call highlights covering financial results, operational progress, and future outlook. Q4 earnings call highlights reveal key financial metrics and guidance that significantly shape investor expectations and stock trajectory.
Stereotaxis Inc. (STXS) reported full-year 2025 financial results. Full-year financial results announcements typically drive significant shifts in investor sentiment and stock performance.
Stereotaxis Inc. (STXS) reported a Q4 net loss and revenue that fell short of analyst estimates. Q4 loss and revenue miss will moderately affect STXS financial performance and market sentiment.
10 Feb
Stereotaxis Inc. has launched an electrophysiology program at Klinikum Furth, aiming to enhance cardiac care through advanced technology. This initiative is expected to improve patient outcomes and expand the company's presence in the electrophysiology market. The program will utilize Stereotaxis' innovative robotic systems to facilitate complex cardiac procedures, aligning with the company's strategy to advance minimally invasive treatments. The launch of the electrophysiology program represents a significant strategic move that could enhance Stereotaxis' market position and financial performance.
9 Feb
Klinikum Fürth has established a leading robotic heart arrhythmia program utilizing Stereotaxis Inc.'s advanced robotic technology. This program aims to enhance the treatment of heart rhythm disorders, positioning Klinikum Fürth as a pioneer in the field. The collaboration is expected to improve patient outcomes and expand the use of robotic-assisted procedures in cardiology. The establishment of a leading program using Stereotaxis technology is likely to significantly enhance the company's market position and investor sentiment.